Semaglutide vs Tesa/IPA Protocol
FDA Approved vs Limited Research
compatible Different pathways; some combine for body composition goals.
Molecular Data
Semaglutide Tesa/IPA Protocol
Weight 4,113.64 Da —
Half-life ~7 days (168 hours) —
Chain 31 amino acids —
Type GLP-1 receptor agonist Dual GH secretagogue combination
Key Benefits
Semaglutide
01 15-20% average body weight reduction
02 Established cardiovascular protection
03 Convenient once-weekly dosing options
04 Comprehensive safety data from extensive trials
05 Flexible injectable and oral formulations
Tesa/IPA Protocol
01 Synergistic GH release from dual pathways
02 More physiological pulsatile GH secretion
03 Tesamorelin's proven lipodystrophy benefits
04 Ipamorelin's clean side effect profile
05 Does not significantly affect cortisol or prolactin
06 Single injection convenience
07 May improve body composition, sleep, and recovery
Dosing Protocols
Semaglutide
0.25mg starting, titrate to 1-2.4mg weekly / Once weekly (same day each week)
Weight Loss Initiation 0.25mg Weekly x 4 weeks, then increase
Weight Loss Maintenance 2.4mg Weekly (after 16-week titration)
Diabetes Management 0.5-1mg Weekly
Cardiovascular Protection 0.5-1mg Weekly
Tolerability-Based 0.25-2.4mg Weekly (individualized)
Tesa/IPA Protocol
200-500mcg total blend per injection / Once daily (evening preferred) or twice daily for advanced protocols
Standard protocol (5/5 blend) 200-400mcg total Once daily (evening)
Enhanced protocol (10/3 blend) 300-500mcg total Once daily (evening)
Twice daily (advanced) 200-300mcg per dose Morning and evening
Side Effects
Semaglutide
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Tesa/IPA Protocol
Injection site reactions (redness, itching)
Water retention (usually transient)
Tingling or numbness in extremities
Joint stiffness
Increased hunger (Ipamorelin effect)
Contraindications
Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of pancreatitis
Active malignancy (GH may promote tumor growth)
Diabetic retinopathy
Pregnancy or breastfeeding
Pituitary disorders
Hypersensitivity to components
Research Evidence
Semaglutide Tesa/IPA Protocol
Status FDA Approved Limited Research
References 6 studies 4 studies
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.